8-K: Recursion Pharmaceuticals Announces FDA Clearance for Novel Cancer Drug, REC-1245, and Merger with Exscientia

Recursion Pharmaceuticals has received FDA clearance for its investigational new drug application for REC-1245, a potential first-in-class RBM39 degrader, and is also planning a merger with Exscientia.

Summary

• Recursion Pharmaceuticals has announced the FDA clearance of its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
• The company plans to initiate a Phase 1/2 clinical trial for REC-1245 in Q4 2024, targeting a patient population of over 100,000 in the US and EU5.
• Recursion's AI-enabled platform facilitated the rapid progression of REC-1245 from target identification to preclinical drug candidate in under 18 months, which is more than twice the speed of the industry average.
• The company also announced a merger with Exscientia, creating a combined entity with approximately $850 million in cash and an expected runway into 2027.
• The combined company anticipates annual synergies of around $100 million or more.
• The merger is expected to close by early 2025, subject to shareholder and regulatory approvals.
• Recursion's Phase 2 trial for REC-994 in Cerebral Cavernous Malformation (CCM) met its primary endpoint of safety, with encouraging trends in exploratory efficacy measures.
• The company is also advancing other clinical programs, including REC-2282 for Neurofibromatosis Type 2 (NF2), REC-4881 for Familial Adenomatous Polyposis (FAP) and AXIN1/APC mutant cancers, and REC-3964 for C. difficile infection.
• Recursion has multiple partnerships with Roche, Genentech, and Bayer, with potential milestone payments exceeding $200 million over the next two years.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the FDA clearance, rapid drug development, strategic merger, and encouraging clinical trial results. The company's strong financial position and multiple partnerships further contribute to the positive outlook.

Positives

• FDA clearance of the IND application for REC-1245 is a significant milestone.
• The rapid development of REC-1245 showcases the efficiency of Recursion's AI-enabled platform.
• The merger with Exscientia creates a financially stronger and more diversified company.
• The combined company has a strong cash position and an extended runway into 2027.
• The Phase 2 results for REC-994 in CCM are encouraging, with positive trends in efficacy.
• Multiple partnerships with major pharmaceutical companies validate Recursion's technology and approach.
• The company has a diverse pipeline of clinical programs targeting various diseases.
• Recursion's platform is designed to accelerate drug discovery and reduce development costs.
• The company has a strong leadership team with experience in both technology and life sciences.
• The company has a strong financial position with ~$474M in cash at the end of Q2 2024.

Negatives

• The merger with Exscientia is subject to shareholder and regulatory approvals, which could introduce uncertainty.
• The clinical development of drug candidates is inherently risky, with a high potential for failure.
• The company is reliant on partnerships for funding and development, which could be subject to changes.
• The company is still in the early stages of clinical development for many of its programs.
• The company is subject to risks related to cyberattacks and other disruptions to its technology systems.
• The company is subject to risks related to inflation and other macroeconomic issues.

Risks

• The clinical trials for REC-1245 and other drug candidates may not be successful.
• The merger with Exscientia may not be completed or may not achieve the expected synergies.
• The company may face challenges in obtaining regulatory approvals for its drug candidates.
• The company may not be able to secure sufficient funding for its development activities.
• The company may face competition from other companies developing similar therapies.
• The company may experience delays in its clinical programs or partnerships.
• The company may be subject to cyberattacks or other disruptions to its technology systems.
• The company may face challenges in attracting and retaining key employees.
• The company may be impacted by inflation and other macroeconomic issues.

Future Outlook

The company anticipates a cash runway into 2027 following the merger with Exscientia and expects to advance multiple clinical programs and partnerships. They also plan to present SYCAMORE trial data at a medical conference and submit the data for publication. The company is also building large-scale causal AI models to generate target hypotheses across cancer and other disease areas.

Management Comments

• Chris Gibson, Ph.D., Co-founder and CEO of Recursion, stated that REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery.
• Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer at Recursion, mentioned that RBM39 degraders may offer a promising therapeutic approach for patients with solid tumors.
• Dr. Jan-Karl Burkhardt, MD, Principal Investigator of the SYCAMORE study, stated that the data from the readout is an impressive start and will provide a valuable contribution to the existing CCM literature and strongly supports the need for a future study.

Industry Context

This announcement highlights the growing trend of using AI and machine learning in drug discovery and development. The merger with Exscientia reflects a move towards consolidation in the biotech industry to leverage complementary technologies and resources. The focus on biomarker-enriched therapies and precision medicine is also a key trend in the pharmaceutical sector.

Comparison to Industry Standards

• The development of REC-1245 from target identification to preclinical candidate in under 18 months is significantly faster than the industry average, which typically takes 3-5 years.
• The company's use of AI and machine learning for drug discovery is comparable to other leading TechBio companies, such as Insitro and Atomwise, but Recursion's focus on large-scale biological datasets and supercomputing capabilities sets it apart.
• The merger with Exscientia is similar to other recent mergers in the biotech space, such as the acquisition of Immunomedics by Gilead, which aim to combine complementary pipelines and technologies.
• The company's partnerships with Roche, Genentech, and Bayer are comparable to other large pharma collaborations, such as the partnership between BioNTech and Pfizer for COVID-19 vaccine development.
• The company's focus on rare diseases and orphan indications is similar to other biotech companies, such as Vertex Pharmaceuticals, which have successfully developed therapies for diseases with limited treatment options.

Stakeholder Impact

• Shareholders will benefit from the increased value of the combined company and the potential for future growth.
• Employees will have opportunities for career advancement and development within the larger organization.
• Patients will have access to new and innovative therapies for various diseases.
• Customers will benefit from the company's expanded product portfolio and services.
• Suppliers will have opportunities to expand their business with the combined company.
• Creditors will have increased confidence in the company's financial stability and ability to repay debts.

Next Steps

• Initiate Phase 1/2 clinical trial for REC-1245 in Q4 2024.
• Advance other clinical programs, including REC-2282, REC-4881, and REC-3964.
• Complete the merger with Exscientia by early 2025.
• Present SYCAMORE trial data at a medical conference and submit the data for publication.
• Meet with the FDA to discuss plans for additional clinical studies for REC-994.
• Continue to build large-scale causal AI models to generate target hypotheses.
• Explore additional partnerships in large, intractable areas of biology.

Key Dates

Keywords

drug discovery, artificial intelligence, clinical trials, biomarker, oncology, RBM39 degrader, REC-1245, merger, Exscientia, partnerships, rare disease, AI, machine learning, pharmaceuticals, biotech